Analyzing laboratory marker changes in AIDS clinical trials
- PMID: 2051307
Analyzing laboratory marker changes in AIDS clinical trials
Abstract
Repeated measurements of laboratory markers of immunologic or disease status, such as CD4 lymphocyte counts and HIV p24 antigen levels, can be important end points in comparative clinical trials. In this report, we consider comparison of treatment groups with respect to such markers, focusing on a distribution-free approach in which each participant's data are characterized by a single summary statistic. The summary statistics examined are (a) the slope of the least-squares regression of the marker, (b) the average of the last r measurements, and (c) the difference between the averages of the last r and the first s measurements. Under various models of marker time trends, these methods are compared with regard to statistical power. It is found that the slope is usually more efficient than the other two types of summaries. Adaptations for missing data are discussed and illustrated in an analysis of CD4 counts from a recent AIDS clinical trial.
Similar articles
-
Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics.Stat Med. 1999 Jul 30;18(14):1803-17; discussion 1819. doi: 10.1002/(sici)1097-0258(19990730)18:14<1803::aid-sim217>3.0.co;2-q. Stat Med. 1999. PMID: 10407251
-
Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.Pediatrics. 2003 Feb;111(2):E168-75. doi: 10.1542/peds.111.2.e168. Pediatrics. 2003. PMID: 12563091
-
Laboratory markers as potential surrogates for clinical outcomes in AIDS trials.J Acquir Immune Defic Syndr (1988). 1990;3 Suppl 2:S69-71. J Acquir Immune Defic Syndr (1988). 1990. PMID: 2121955 No abstract available.
-
An approach to the validation of markers for use in AIDS clinical trials.Clin Infect Dis. 1997 May;24(5):764-74. doi: 10.1093/clinids/24.5.764. Clin Infect Dis. 1997. PMID: 9142767 Review.
-
Human immunodeficiency virus infection, Part I.Dis Mon. 1998 Oct;44(10):545-606. doi: 10.1016/s0011-5029(98)90014-1. Dis Mon. 1998. PMID: 9814367 Review.
Cited by
-
AIDS and COVID: A tale of two pandemics and the role of statisticians.Stat Med. 2021 May 20;40(11):2499-2510. doi: 10.1002/sim.8936. Stat Med. 2021. PMID: 33963579 Free PMC article.
-
A comparison of missing data methods for hypothesis tests of the treatment effect in substance abuse clinical trials: a Monte-Carlo simulation study.Subst Abuse Treat Prev Policy. 2008 Jun 3;3:13. doi: 10.1186/1747-597X-3-13. Subst Abuse Treat Prev Policy. 2008. PMID: 18522752 Free PMC article.
-
Power and sample-size calculations for trials that compare slopes over time: Introducing the slopepower command.Stata J. 2021 Sep;21(3):575-601. doi: 10.1177/1536867X211045512. Epub 2021 Oct 4. Stata J. 2021. PMID: 37476648 Free PMC article.
-
Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge.Neuroimage. 2015 Dec;123:149-64. doi: 10.1016/j.neuroimage.2015.07.087. Epub 2015 Aug 11. Neuroimage. 2015. PMID: 26275383 Free PMC article.
-
The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials.J Subst Abuse Treat. 2009 Jul;37(1):54-63. doi: 10.1016/j.jsat.2008.09.011. Epub 2008 Nov 13. J Subst Abuse Treat. 2009. PMID: 19008067 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials